Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 1;105-B(5):559-567.
doi: 10.1302/0301-620X.105B5.BJJ-2022-1231.R1.

Giant cell tumour of bone

Affiliations

Giant cell tumour of bone

Ahmed Aoude et al. Bone Joint J. .

Abstract

Giant cell tumour of bone (GCTB) is a locally aggressive lesion that is difficult to treat as salvaging the joint can be associated with a high rate of local recurrence (LR). We evaluated the risk factors for tumour relapse after treatment of a GCTB of the limbs. A total of 354 consecutive patients with a GCTB underwent joint salvage by curettage and reconstruction with bone graft and/or cement or en bloc resection. Patient, tumour, and treatment factors were analyzed for their impact on LR. Patients treated with denosumab were excluded. There were 53 LRs (15%) at a mean 30.5 months (5 to 116). LR was higher after curettage (18.4%) than after resection (4.6%; p = 0.008). Neither pathological fracture (p = 0.240), Campanacci grade (p = 0.734), soft-tissue extension (p = 0.297), or tumour size (p = 0.872) affected the risk of recurrence. Joint salvage was possible in 74% of patients overall (262/354), and 98% after curettage alone (262/267). Of 49 patients with LR after curettage, 44 (90%) underwent repeated curettage and joint salvage. For patients treated by curettage, only age less than 30 years (p = 0.042) and location in the distal radius (p = 0.043) predicted higher LR. The rate of LR did not differ whether cement or bone graft was used (p = 0.753), but may have been reduced by the use of hydrogen peroxide (p = 0.069). Complications occurred in 15.3% of cases (54/354) and did not differ by treatment. Most patients with a GCTB can undergo successful joint salvage by aggressive curettage, even in the presence of a soft-tissue mass, pathological fracture, or a large lesion, with an 18.4% risk of local recurrence. However, 90% of local relapses after curettage can be treated by repeat joint salvage. Maximizing joint salvage is important to optimize long-term function since most patients with a GCTB are young adults. Younger patients and those with distal radius tumours treated with joint-sparing procedures have a higher rate of local relapse and may require more aggressive treatment and closer follow-up.

PubMed Disclaimer

Conflict of interest statement

None declared.

References

    1. Turcotte RE , Wunder JS , Isler MH , et al. Giant cell tumor of long bone: a Canadian Sarcoma Group study . Clin Orthop Relat Res . 2002 ; 397 ( 397 ): 248 – 258 . 10.1097/00003086-200204000-00029 , 11953616
    1. Campanacci M , Baldini N , Boriani S , Sudanese A . Giant-cell tumor of bone . J Bone Joint Surg Am . 1987 ; 69 ( 1 ): 106 – 114 . 10.2106/00004623-198769010-00018 , 3805057
    1. Gulia A , Puri A , Chorge S , Panda PK . Epidemiological data and case load spectrum of patients presenting to bone and soft tissue disease management group at a tertiary cancer center . Indian J Cancer . 2016 ; 53 ( 2 ): 333 – 338 . 10.4103/0019-509X.197734 , 28071641
    1. Guo W , Xu W , Huvos AG , Healey JH , Feng C . Comparative frequency of bone sarcomas among different racial groups . Chin Med J (Engl) . 1999 ; 112 ( 12 ): 1101 – 1104 . 11721448
    1. Skubitz KM . Giant cell tumor of bone: current treatment options . Curr Treat Options Oncol . 2014 ; 15 ( 3 ): 507 – 518 . 10.1007/s11864-014-0289-1 , 24788576